Patents by Inventor Kamlesh Singh

Kamlesh Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mixed chopping and correlated double sampling two-step analog-to-digital converter
    Patent number: 10615818
    Abstract: A two-step, hybrid analog-to-digital converter (ADC) includes a Delta-Sigma ADC that employs chopping to resolve MSBs, a Nyquist ADC that employs correlated double sampling (CDS) to resolve LSBs, and a combiner that combines the MSBs and the LSBs to generate a digital output signal. The Delta-Sigma ADC has first and second integrators where, after resolving the MSBs, the first integrator is re-configured to function as a reference buffer for the Nyquist ADC and the second integrator is re-configured to function as the Nyquist ADC.
    Type: Grant
    Filed: June 2, 2019
    Date of Patent: April 7, 2020
    Assignee: NXP USA, Inc.
    Inventors: Kamlesh Singh, Vikram Varma
  • PROCESS FOR PREPARATION OF APALUTAMIDE
    Publication number: 20200071287
    Abstract: The present invention relates to a process for the preparation of apalutamide. In particular, the present invention relates to a process for the preparation of apalutamide and its intermediates. The present invention also relates to pharmaceutical compositions comprising apalutamide.
    Type: Application
    Filed: March 27, 2019
    Publication date: March 5, 2020
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Kumar Kamlesh SINGH, Nikhil Amar SINGH, Ganpat Dan Shimbhu CHARAN, Nimeshkumar Mukeshkumar SHAH
  • PROCESS FOR PREPARATION OF APALUTAMIDE
    Publication number: 20200024250
    Abstract: The present invention relates to a process for the preparation of apalutamide. In particular, the present invention relates to a process for the preparation of apalutamide and its intermediates. The present invention also relates to pharmaceutical compositions comprising apalutamide.
    Type: Application
    Filed: September 27, 2019
    Publication date: January 23, 2020
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Kumar Kamlesh SINGH, Nikhil Amar SINGH, Ganpat Dan Shimbhu CHARAN, Nimeshkumar Mukeshkumar SHAH
  • Amorphous vortioxetine and salts thereof
    Patent number: 10414741
    Abstract: The present invention relates to an amorphous vortioxetine and salts thereof. In particular, the invention relates to a process for the preparation of an amorphous vortioxetine hydrobromide. Further, the invention also relates to a process for preparation of amorphous vortioxetine free base. The invention also relates to pharmaceutical compositions comprising an amorphous vortioxetine or hydrobromide salt thereof for oral administration for treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: September 17, 2019
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Shri Prakash Dhar Dwivedi, Kumar Kamlesh Singh, Jitendra Maganbhai Gajera, Dinesh Kumar Raikwar, Brij Khera
  • Crystalline form of rifaximin and process for its preparation
    Patent number: 9988398
    Abstract: A novel crystalline form of rifaximin and process for its preparation are described. A pharmaceutical composition comprising crystalline rifaximin is also described.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: June 5, 2018
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Kumar Kamlesh Singh, Nikhil Amar Singh, Prashant Rameshchandra Bhatt, Amol Kashinath Patil
  • Amorphous form of linagliptin and process for preparation thereof
    Patent number: 9879011
    Abstract: The present invention relates to an amorphous form of linagliptin and processes for the preparation thereof. The invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of an amorphous form of linagliptin and use of the composition for treatment of diabetes especially type-I or type-II, prediabetes or reduction of glucose tolerance.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: January 30, 2018
    Assignee: Cadila Healthcare Limited
    Inventors: Shriprakash Dhar Dwivedi, Ashok Prasad, Kuldeep Natwarlal Jain, Kumar Kamlesh Singh, Jitendra Maganbhai Gajera
  • NOVEL CRYSTALLINE FORM OF RIFAXIMIN AND PROCESS FOR ITS PREPARATION
    Publication number: 20170349608
    Abstract: A novel crystalline form of rifaximin and process for its preparation are described. A pharmaceutical composition comprising crystalline rifaximin is also described.
    Type: Application
    Filed: June 6, 2017
    Publication date: December 7, 2017
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Kumar Kamlesh SINGH, Nikhil Amar SINGH, Prashant Rameshchandra BHATT, Amol Kashinath PATIL
  • PROCESS FOR PREPARATION OF ANDROGEN RECEPTOR ANTAGONIST
    Publication number: 20170158643
    Abstract: The present invention provides an isopropanol solvate of enzalutamide. The present invention also provides a process for the preparation of androgen receptor antagonist. In particular, the present invention provides a process for the preparation of enzalutamide or its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof.
    Type: Application
    Filed: February 23, 2017
    Publication date: June 8, 2017
    Inventors: Shri Prakash Dhar Dwivedi, Kumar Kamlesh Singh, Ganpat Dan Shimbhu Charan
  • Process for preparation of androgen receptor antagonist
    Patent number: 9611225
    Abstract: The present invention provides an isopropanol solvate of enzalutamide. The present invention also provides a process for the preparation of androgen receptor antagonist. In particular, the present invention provides a process for the preparation of enzalutamide or its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: April 4, 2017
    Assignee: Cadila Healthcare Limited
    Inventors: Shri Prakash Dhar Dwivedi, Kumar Kamlesh Singh, Ganpat Dan Shimbhu Charan
  • Process for the preparation of apixaban
    Patent number: 9603846
    Abstract: A crystalline Form N-1 of apixaban substantially free from one or more of: 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid; 7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-1-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; or methyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate, relative to apixaban by area percentage of HPLC and having a mean particle size equal to or greater than 100 ?m.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: March 28, 2017
    Assignee: Cadila Healthcare Limited
    Inventors: Brij Khera, Kumar Kamlesh Singh, Santosh Devidas Diwakar, Sunil Dnyaneshwar Narode, Hiteshkumar Natwarlal Suthar
  • Process for the preparation of amorphous imatinib mesylate
    Patent number: 9439903
    Abstract: The field of the invention relates to a process for the preparation of amorphous imatinib mesylate. In particular, the invention relates to a process for the preparation of stable amorphous imatinib mesylate. More particularly, the invention relates to pharmaceutical compositions that includes the stable amorphous imatinib messylate together along with its excipients.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: September 13, 2016
    Assignee: Cadila Healthcare Limited
    Inventors: Shriprakash Dhar Dwivedi, Kumar Kamlesh Singh, Ganpant Dan Shimbu Charan, Chetan Jayantibhai Vasava
  • Process for the preparation of sitagliptin phosphate
    Patent number: 9409912
    Abstract: The present invention relates to a method for the preparation of sitagliptin phosphate and sitagliptin phosphate anhydrous of Formula (I?) and monohydrate of Formula (I),
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: August 9, 2016
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Shri prakash Dhar Dwivedi, Kumar Kamlesh Singh, Sunil Dnyaneshwar Narode, Dhaval Jashvantbhai Patel, Kirtipalsinh Sajjansinh Solanki
  • AN AMORPHOUS VORTIOXETINE AND SALTS THEREOF
    Publication number: 20160214949
    Abstract: The present invention relates to an amorphous vortioxetine and salts thereof. In particular, the invention relates to a process for the preparation of an amorphous vortioxetine hydrobromide. Further, the invention also relates to a process for preparation of amorphous vortioxetine free base. The invention also relates to pharmaceutical compositions comprising an amorphous vortioxetine or hydrobromide salt thereof for oral administration for treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).
    Type: Application
    Filed: September 30, 2014
    Publication date: July 28, 2016
    Inventors: Shri Prakash Dhar DWIVEDI, Kumar Kamlesh SINGH, Jitendra Maganbhai GAJERA, Dinesh Kumar RAIKWAR, Brij KHERA
  • Amorphous form of apremilast
    Patent number: 9351957
    Abstract: The present invention provides an amorphous form of apremilast and process for preparation thereof. The present invention also provides a pharmaceutical composition comprising an amorphous apremilast and one or more of pharmaceutically acceptable carriers, excipients or diluents used for the treatment of active psoriatic arthritis.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: May 31, 2016
    Assignee: Cadila Healthcare Limited
    Inventors: Brij Khera, Kumar Kamlesh Singh, Santosh Devidas Diwakar, Chetan Jayantibhai Vasava, Anil Kumar Shivprasad Tiwari
  • PROCESS FOR THE PREPARATION OF APIXABAN
    Publication number: 20160143894
    Abstract: A crystalline Form N-1 of apixaban substantially free from one or more of: 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid; 7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-1-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; or methyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate, relative to apixaban by area percentage of HPLC and having a mean particle size equal to or greater than 100 ?m.
    Type: Application
    Filed: November 24, 2015
    Publication date: May 26, 2016
    Inventors: Brij KHERA, Kumar Kamlesh SINGH, Santosh Devidas DIWAKAR, Sunil Dnyaneshwar NARODE, Hiteshkumar Natwarlal SUTHAR
  • AN IMPROVED PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF
    Publication number: 20160113912
    Abstract: The present invention relates to an improved process for the preparation of apixaban and intermediates thereof. In particular, the invention relates to an improved process for the preparation of an amorphous form of apixaban. The invention also relates to a pharmaceutical composition comprising an amorphous form of apixaban for oral administration as an antithrombotic agent.
    Type: Application
    Filed: June 17, 2014
    Publication date: April 28, 2016
    Inventors: Shriprakash Dhar DWIVEDI, Kumar Kamlesh SINGH, Nitin TANDON, Digambar WARE
  • Process for preparation of amorphous form of dasatinib
    Patent number: 9249134
    Abstract: A stable amorphous form of dasatinib of Formula (I) wherein amorphous dasatinib after exposure to a relative humidity of 75% at 40 ° C. or 60% at 25 ° C. for a period of at least three months doesn't change to crystalline form and a process for the preparation of the amorphous form of dasatinib of Formula (I).
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: February 2, 2016
    Assignee: Cadila Healthcare Limited
    Inventors: Shriprakash Dhar Dwivedi, Kumar Kamlesh Singh, Nikhil Amar Singh, Amol Kashinath Patil
  • AMORPHOUS FORM OF APREMILAST
    Publication number: 20150283249
    Abstract: The present invention provides an amorphous form of apremilast and process for preparation thereof. The present invention also provides a pharmaceutical composition comprising an amorphous apremilast and one or more of pharmaceutically acceptable carriers, excipients or diluents used for the treatment of active psoriatic arthritis.
    Type: Application
    Filed: April 2, 2015
    Publication date: October 8, 2015
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Brij KHERA, Kumar Kamlesh SINGH, Santosh Devidas DIWAKAR, Chetan Jayantibhai VASAVA, Anil Kumar Shivprasad TIWARI
  • PROCESS FOR PREPARATION OF ANDROGEN RECEPTOR ANTAGONIST
    Publication number: 20150210649
    Abstract: The present invention provides an isopropanol solvate of enzalutamide. The present invention also provides a process for the preparation of androgen receptor antagonist. In particular, the present invention provides a process for the preparation of enzalutamide or its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof.
    Type: Application
    Filed: January 27, 2015
    Publication date: July 30, 2015
    Inventors: Shri Prakash Dhar Dwivedi, Kumar Kamlesh Singh, Ganpat Dan Shimbu Charan
  • PROCESS FOR THE PREPARATION OF SITAGLIPTIN PHOSPHATE
    Publication number: 20150087834
    Abstract: The present invention relates to a method for the preparation of sitagliptin phosphate and sitagliptin phosphate anhydrous of Formula (I?) and monohydrate of Formula (I),
    Type: Application
    Filed: March 20, 2014
    Publication date: March 26, 2015
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Shri prakash Dhar DWIVEDI, Kumar Kamlesh SINGH, Sunil Dnyaneshwar NARODE, Dhaval Jashvantbhai PATEL, Kirtipalsinh Sajjansinh SOLANKI